Brief: Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
05/02/2025 12:36
Feb 5 (Reuters) - Adicet Bio Inc ACET.O :
* ADICET BIO RECEIVES FDA FAST TRACK DESIGNATION FOR ADI-001
FOR
THE TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
WITH EXTRARENAL INVOLVEMENT
Source text: ID:nBw6rbxg5a
Further company coverage: ACET.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ADICET Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis
Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-212
Adicet Bio, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary